Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this report, a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis and alopecia areata achieved complete remission of hair loss after treatment with baricitinib.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study found that testosterone replacement in castrated male rats counteracted endotoxemia-induced arterial baroreflex dysfunction without significantly affecting neuroinflammation.

In this study, baricitinib was effective in improving hair regrowth in patients with severe alopecia areata over one year, especially when treatment began within four years of symptom onset.

This retrospective study observed that switching from tofacitinib to baricitinib improved hair growth in patients with alopecia areata, particularly for previous non-responders, and noted fewer side effects with baricitinib.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

Baricitinib is a safe and effective treatment for severe alopecia areata.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This study explored the creation of 3D-printed baricitinib pills using polylactic acid and found that the doughnut-shaped tablets increased surface area and drug release, with 59% released from the higher concentration pill over 24 hours.

This case report presents the first successful treatment of perifolliculitis capitis abscedens et suffodiens using a regimen of adalimumab and baricitinib, resulting in almost complete healing after nine months.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Results are not reported in this article by Zizhuo Li et al. on baricitinib as a treatment for lichen planopilaris.

This study aims to evaluate whether a subset of patients experience undetected hypothyroidism, termed the "famine response," during rapid weight loss after bariatric surgery, which may impact weight loss outcomes. Results are not reported in this abstract.

This study examines the potential effectiveness of Barever natural hair inhibitor, which includes papaya and other herbal ingredients, in reducing hair growth permanently when applied after hair removal.

This article discusses the role of barbershops in public health education for skin disorders and suggests that educating barbers could help in early detection and prevention of some conditions; it reports no new experimental findings.

This review highlights that while bariatric surgery is effective for weight loss and health improvement, it also presents significant postoperative physical and psychological challenges, emphasizing the need for holistic care to ensure long-term success in treating obesity.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.

This review synthesizes existing research on the multilayered defense system of the skin, highlighting how physical, chemical, immune, and microbial barriers work together to maintain skin health, with disruptions in one often leading to broader barrier dysfunctions.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

This literature review on JAK inhibitors reports that ocular side effects are rare but could be significant, with an inability to establish a causal link. Clinicians are advised to monitor such adverse events and report them to drug safety agencies.

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

This study suggests that while adding baricitinib to formularies may increase costs for government hospitals, it could expand treatment options and potentially improve outcomes for patients with AA. Further analyses are recommended to assess its cost-effectiveness in terms of outcomes improvement.

This article discusses alopecia areata and lichen planopilaris, providing a review of their clinical characteristics and reporting no new research findings; the authors underscore the potential progression and distinctive features of each condition.

Baricitinib helps with early hair regrowth in people with alopecia areata.

This review discusses Barrett's esophagus, its risk factors, diagnostic methods, and treatment options, emphasizing its potential for malignant degeneration and the importance of personalized treatment based on patient factors.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.